mazindol has been researched along with Gelineau Syndrome in 11 studies
Mazindol: Tricyclic anorexigenic agent unrelated to and less toxic than AMPHETAMINE, but with some similar side effects. It inhibits uptake of catecholamines and blocks the binding of cocaine to the dopamine uptake transporter.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Mazindol is a tricyclic, anorectic, non-amphetamine stimulant used in narcolepsy and obesity since 1970." | 9.17 | Mazindol in narcolepsy and idiopathic and symptomatic hypersomnia refractory to stimulants: a long-term chart review. ( Arnulf, I; Bayard, S; Cock, VC; Dauvilliers, Y; Franco, P; Inocente, CO; Konofal, E; Lecendreux, M; Leu-Semenescu, S; Nittur, N; Scholtz, S, 2013) |
| "Twenty patients with the narcoleptic syndrome were treated separately with dexamphetamine sulphate tablets 10 and 30 mg, Dexedrine Spansules 10 mg, mazindol 4 mg, and fencamfamin hydrochloride 60 mg daily." | 6.66 | Amphetamine, mazindol, and fencamfamin in narcolepsy. ( Brincat, S; Parkes, JD; Schachter, M; Shindler, J, 1985) |
| "Selegiline was compared to no treatment (7 subjects) or conventional central stimulant drugs, including dexamphetamine or mazindol (14 subjects)." | 5.27 | Selegiline in narcolepsy. ( Jenner, P; Langdon, N; Lock, CB; Parkes, JD; Roselaar, SE, 1987) |
| "Thirty-four subjects with the narcoleptic syndrome were treated with mazindol 3--8 mg daily for 1 year." | 5.26 | Mazindol in the treatment of narcolepsy. ( Parkes, JD; Schachter, M, 1979) |
| "Mazindol is a tricyclic, anorectic, non-amphetamine stimulant used in narcolepsy and obesity since 1970." | 5.17 | Mazindol in narcolepsy and idiopathic and symptomatic hypersomnia refractory to stimulants: a long-term chart review. ( Arnulf, I; Bayard, S; Cock, VC; Dauvilliers, Y; Franco, P; Inocente, CO; Konofal, E; Lecendreux, M; Leu-Semenescu, S; Nittur, N; Scholtz, S, 2013) |
| "Twenty patients with the narcoleptic syndrome were treated separately with dexamphetamine sulphate tablets 10 and 30 mg, Dexedrine Spansules 10 mg, mazindol 4 mg, and fencamfamin hydrochloride 60 mg daily." | 2.66 | Amphetamine, mazindol, and fencamfamin in narcolepsy. ( Brincat, S; Parkes, JD; Schachter, M; Shindler, J, 1985) |
| "Onset of narcolepsy is unusual at this age and the temporal relationship following radiotherapy suggests this treatment was implicated." | 1.32 | Acquired narcolepsy in an acromegalic patient who underwent pituitary irradiation. ( de Silva, RN; Dempsey, OJ; Douglas, NJ; McGeoch, P, 2003) |
| "Selegiline was compared to no treatment (7 subjects) or conventional central stimulant drugs, including dexamphetamine or mazindol (14 subjects)." | 1.27 | Selegiline in narcolepsy. ( Jenner, P; Langdon, N; Lock, CB; Parkes, JD; Roselaar, SE, 1987) |
| "Thirty-four subjects with the narcoleptic syndrome were treated with mazindol 3--8 mg daily for 1 year." | 1.26 | Mazindol in the treatment of narcolepsy. ( Parkes, JD; Schachter, M, 1979) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (63.64) | 18.7374 |
| 1990's | 2 (18.18) | 18.2507 |
| 2000's | 1 (9.09) | 29.6817 |
| 2010's | 1 (9.09) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nittur, N | 1 |
| Konofal, E | 1 |
| Dauvilliers, Y | 1 |
| Franco, P | 1 |
| Leu-Semenescu, S | 1 |
| Cock, VC | 1 |
| Inocente, CO | 1 |
| Bayard, S | 1 |
| Scholtz, S | 1 |
| Lecendreux, M | 1 |
| Arnulf, I | 1 |
| Dempsey, OJ | 1 |
| McGeoch, P | 1 |
| de Silva, RN | 1 |
| Douglas, NJ | 1 |
| Vespignani, H | 2 |
| Barroche, G | 2 |
| Escaillas, JP | 1 |
| Weber, M | 2 |
| Parkes, JD | 4 |
| Schachter, M | 2 |
| Alvarez, B | 1 |
| Dahlitz, M | 1 |
| Grimshaw, J | 1 |
| Lange, KW | 1 |
| Shindler, J | 1 |
| Brincat, S | 1 |
| Roselaar, SE | 1 |
| Langdon, N | 1 |
| Lock, CB | 1 |
| Jenner, P | 1 |
| Iijima, S | 1 |
| Sugita, Y | 1 |
| Teshima, Y | 1 |
| Hishikawa, Y | 1 |
| Atlas, P | 1 |
| Salín-Pascual, RJ | 1 |
| de la Fuente, JR | 1 |
1 review available for mazindol and Gelineau Syndrome
| Article | Year |
|---|---|
[Narcolepsy].
Topics: Adolescent; Adult; Amphetamine; Cataplexy; Child; Clomipramine; Diagnosis, Differential; Female; Hum | 1990 |
2 trials available for mazindol and Gelineau Syndrome
| Article | Year |
|---|---|
Mazindol in narcolepsy and idiopathic and symptomatic hypersomnia refractory to stimulants: a long-term chart review.
Topics: Adolescent; Adult; Aged; Blood Pressure; Cataplexy; Central Nervous System Stimulants; Child; Female | 2013 |
Amphetamine, mazindol, and fencamfamin in narcolepsy.
Topics: Adult; Aged; Amphetamines; Central Nervous System Stimulants; Female; Humans; Indoles; Male; Mazindo | 1985 |
8 other studies available for mazindol and Gelineau Syndrome
| Article | Year |
|---|---|
Acquired narcolepsy in an acromegalic patient who underwent pituitary irradiation.
Topics: Acromegaly; Carrier Proteins; Central Nervous System Stimulants; Humans; Intracellular Signaling Pep | 2003 |
Importance of mazindol in the treatment of narcolepsy.
Topics: Female; Humans; Indoles; Male; Mazindol; Narcolepsy | 1984 |
Mazindol in the treatment of narcolepsy.
Topics: Adolescent; Adult; Aged; Female; Humans; Indoles; Male; Mazindol; Middle Aged; Narcolepsy | 1979 |
Mazindol in long-term treatment of narcolepsy.
Topics: Adolescent; Adult; Aged; Female; Humans; Male; Mazindol; Middle Aged; Narcolepsy | 1991 |
Selegiline in narcolepsy.
Topics: Adult; Affect; Aged; Cataplexy; Dextroamphetamine; Humans; Male; Mazindol; Middle Aged; Narcolepsy; | 1987 |
Therapeutic effects of mazindol on narcolepsy.
Topics: Adult; Cataplexy; Female; Humans; Indoles; Male; Mazindol; Middle Aged; Narcolepsy | 1986 |
[Value of mazindol in Gélineau's disease. Apropos of 10 cases].
Topics: Adolescent; Adult; Catalepsy; Clomipramine; Drug Therapy, Combination; Female; Humans; Indoles; Male | 1986 |
[Advances in the psychopharmacological management of the narcoleptic patient].
Topics: Animals; Clonidine; Dogs; Humans; Hydroxybutyrates; Indoles; Mazindol; Narcolepsy; Sleep, REM; Sodiu | 1985 |